Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
Adult
Aged
Aged, 80 and over
Databases, Factual
/ statistics & numerical data
Female
Humans
Intestinal Neoplasms
/ pathology
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Recurrence, Local
Neuroendocrine Tumors
/ pathology
Outcome Assessment, Health Care
/ methods
Pancreatic Neoplasms
/ pathology
Stomach Neoplasms
/ pathology
United States
Young Adult
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
20
1
2022
Statut:
ppublish
Résumé
Current National Comprehensive Cancer Network guidelines for gastroenteropancreatic neuroendocrine tumors (GEPNETs) recommend complete (R0) surgical resection of the primary tumor and metastases, if feasible. However, large multicenter studies of recurrence patterns of GEPNETs after resection have not been performed. Patients 18 years or older who presented to 7 participating National Comprehensive Cancer Network institutions between 2004 and 2008 with a new diagnosis of a small bowel, pancreas, or colon/rectum neuroendocrine tumor (NET) and underwent R0 resection of the primary tumor, and synchronous metastases, if present, were included in this analysis. Descriptive statistics and Kaplan-Meier estimates were used to calculate recurrence rates and time-associated end points, respectively. Of 294 patients with GEPNETs, 50% were male, 88% were White, and 99% had Eastern Cooperative Oncology Group performance status 0 to 1. The median age was 55 years (range, 20-90). The median follow-up time from R0 resection was 62.1 months. Recurrence rates were 18% in small bowel NETs (n = 110), 26% in pancreatic NETs (n = 141), and 10% in colon/rectum NETs (n = 50). The frequency of surveillance imaging was highly variable. R0 resection was associated with variable risk of recurrence across subtypes. Further research to inform refinement of guidelines for the appropriate duration of surveillance after R0 resection is needed.
Identifiants
pubmed: 33939661
doi: 10.1097/MPA.0000000000001791
pii: 00006676-202104000-00004
pmc: PMC8097723
mid: NIHMS1677045
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-512Subventions
Organisme : AHRQ HHS
ID : K12 HS021700
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer . 2009;115:741–751.
Singh S, Chan DL, Moody L, et al. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol . 2018;4:583–585.
Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg . 1998;187:88–92; discussion 92–93.
Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) . 2010;12:427–433.
House MG, Cameron JL, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg . 2006;10:138–145.
National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 2.2020). July 24, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf . Accessed September 20, 2020.
Arnold R, Chen YJ, Costa F, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology . 2009;90:227–233.
Pape UF, Maasberg S, Jann H, et al. Management of follow-up of neuroendocrine neoplasias. Best Pract Res Clin Endocrinol Metab . 2016;30:129–140.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol . 2008;26:3063–3072.
Pape UF, Berndt U, Müller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer . 2008;15:1083–1097.
Van Gompel JJ, Sippel RS, Warner TF, et al. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg . 2004;28:387–392.
Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer . 2013;20:187–196.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis . 1987;40:373–383.
Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol . 1994;47:1245–1251.
Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual . 7th ed. New York, NY: Springer-Verlag; 2010. Available at: https://www.springer.com/gp/book/9780387884424 . Accessed March 23, 2020.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available at: http://www.R-project.org/ . Accessed August 1, 2020.
Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg . 2003;197:29–37.
Chawla A, Williams RT, Sich N, et al. Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors. J Surg Oncol . 2018;118:983–990.
National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 1.2019). March 5, 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine_blocks.pdf . Accessed March 3, 2020.
Singh S, Moody L, Chan DL, et al. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol . 2018;4:1597–1604.
Shen C, Dasari A, Chu Y, et al. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol Off J Eur Soc Med Oncol . 2017;28:1582–1589.
Knigge U, Capdevila J, Bartsch DK, et al. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology . 2017;105:310–319.
National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 1.2015). November 11, 2014. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine_blocks.pdf . Accessed January 25, 2020.
Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med . 2007;357:2277–2284.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol . 2017;3:1335–1342.
Shen C, Gu D, Zhou S, et al. Racial differences in the incidence and survival of patients with neuroendocrine tumors. Pancreas . 2019;48:1373–1379.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med . 2018;59:66–74.
Graham MM, Gu X, Ginader T, et al. 68 Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J Nucl Med . 2017;58:1452–1458.